A next-generation Biotechnology company creating off-the-shelf cellular medicines for Cancer, Infectious Diseases, and Degenerative Diseases.
GX Acquisition Corp has entered into a definitive agreement with Celularity.
News from Celularity:
Celularity Announces Full Year 2024 Operating and Financial Results
Read More Net revenues for the year ending December 31, 2024, totaled $54.2 million, an increase of $31.4 million, or 138.1%, compared to the previous year. FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced operating and financial results for…
Continue Reading Celularity Announces Full Year 2024 Operating and Financial Results
Celularity Welcomes CMS Action on Medicare Local Coverage Determination for Skin Substitutes Products
Read More Action delays to January 1, 2026, the effective date of a Biden-era Medicare LCD for skin substitute products used to treat diabetic foot ulcers and venous leg ulcers FLORHAM PARK, N.J., April 14, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, welcomes action…
Celularity Announces Publication of “Senescence, NK cells, and cancer: navigating the crossroads of aging and disease” in the April 4, 2025, Issue of Frontiers in Immunology
Read More Highlights the unique therapeutic potential of Celularity clinical-stage candidate CYNK-001 in age-related diseases FLORHAM PARK, N.J., April 07, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced a key publication in the April 4, 2025, issue of the prestigious peer-reviewed journal Frontiers in Immunology, the…
Celularity Receives FDA Tissue Reference Group Recommendation Letters for its Natalin and Acelagraft™ Wound Care Products
Read More Natalin and Acelagraft are the latest additions to Celularity’s portfolio of HCT/P 361 products for use in the treatment of partial and full thickness acute and chronic wounds FLORHAM PARK, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced that on…
Celularity Enters Strategic Collaboration Agreement with Clinical Stage Cell Therapy Company
Read More Leverages Celularity World-class Manufacturing Capabilities FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) — Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a cellular and regenerative medicine company, today announced that it has entered into a Master Services Collaboration Agreement with BlueSphere Bio, Inc. (BSB) covering manufacturing activities for certain BSB cell therapy…
MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs
Read More FLORHAM PARK, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) — Celularity issues the following announcement on behalf of the members of the MASS Coalition: MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs President Trump’s Freeze Order Applies to Skin Substitute LCDs – LCDs will not be effective until at least April 13, 2025 The…
Continue Reading MASS Coalition Welcomes Trump Order Freezing Skin Substitute LCDs
[fts_twitter twitter_name=celularity tweets_count=6 cover_photo=no stats_bar=no show_retweets=no show_replies=no]